Short Interest in Co-Diagnostics, Inc. (NASDAQ:CODX) Decreases By 7.8%

Co-Diagnostics, Inc. (NASDAQ:CODX) saw a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 208,700 shares, a decrease of 7.8% from the October 15th total of 226,400 shares. Based on an average daily volume of 246,900 shares, the short-interest ratio is currently 0.8 days.

Institutional Investors Weigh In On Co-Diagnostics

An institutional investor recently bought a new position in Co-Diagnostics stock. Jane Street Group LLC acquired a new stake in shares of Co-Diagnostics, Inc. (NASDAQ:CODX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 44,124 shares of the company’s stock, valued at approximately $55,000. Jane Street Group LLC owned approximately 0.14% of Co-Diagnostics as of its most recent filing with the Securities & Exchange Commission. 14.99% of the stock is currently owned by institutional investors.

Co-Diagnostics Trading Down 3.6 %

Shares of NASDAQ:CODX opened at $1.06 on Monday. The firm has a market cap of $33.85 million, a price-to-earnings ratio of -0.77 and a beta of -0.84. Co-Diagnostics has a 1 year low of $1.00 and a 1 year high of $2.23. The business has a fifty day simple moving average of $1.23 and a 200 day simple moving average of $1.26.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “neutral” rating and set a $1.50 price target on shares of Co-Diagnostics in a report on Monday, November 11th.

About Co-Diagnostics

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.